Q&A with Alumna Dr. Jackson
In July 2018, the National Institutes of Health (NIH) granted a $26.4 million Clinical and Translational Science Award (CTSA) to Rebecca Jackson, MD, professor of Endocrinology, Diabetes and Metabolism. This amount is one of the largest grants ever received by Ohio State's College of Medicine. Also associate dean for Clinical Research and director of the Center for Clinical and Translational Science (CCTS), Dr. Jackson plans to use the funds to create programs that grow research cores and to establish career development initiatives for translational scientists and members of the research team.
“Rebecca Jackson, MD, receives one of the largest grants ever received by Ohio State's College of Medicine.”Click to tweet this story
Dr. Jackson graduated from The Ohio State University College of Medicine in 1978 and returned to Ohio State in 1983 following her training programs. Her years of outstanding service to the College of Medicine continue to garner her national awards and accolades, including being named a 2018 Castle Connolly Top Doctor.
Q. Congratulations on receiving an exemplary score on your CTSA grant application. How did you accomplish this?
A. We did receive an incredible score on our first submission. This is testament to the hard work and tremendous successes of a large and passionate team of researchers and program staff that help facilitate the work and career development of our researchers across Ohio State.
Q. This is the center's third five-year cycle of funding from the National Center for Advancing Translational Sciences since 2008. How will these resources be utilized?
A. This award will allow us to continue to contribute to the national conversation on translational research. CCTS will further expand its clinical and translational research infrastructure, pilot funding initiatives and education and career development programs for investigators and the scientific workforce. We convene, catalyze and support new interdisciplinary team science. The grant promotes and supports innovative research taking place at Ohio State and Nationwide Children's Hospital to advance breakthrough discoveries that can ultimately help us accelerate many life-saving efforts. This brings transformational care to our patients.
Q. Who will participate in this research?
A. The CCTS is a partnership among Ohio State Wexner Medical Center, the 15 university colleges, NCH and more than 75 central Ohio community stakeholders representing patients, community organizations, industry and government. There are more than 4,400 faculty, staff and researchers participating as members of the CCTS.
Q. What are some of the outcomes related to this research?
A. Our goal is to support the most innovative science and help create an environment that translates those findings to enhance health. Toward that goal, a critical outcome of our success is to broadly disseminate that new knowledge to the scientific community to advance scientific translation. Over the past 10 years, research funded or supported by CCTS research cores have resulted in more than 1,400 publications that have been cited by other scientists more than 55,000 times.
There have been advances across the translational spectrum from the lab to the clinic to communities, including the development of an innovative laboratory model for studying sarcoidosis and tuberculosis; pharmacokinetic studies of chemicals in foods that help determine the "correct dose" of food that might reduce risk for cancers and other diseases; and the development of new electronic health record decision support tools to help clinicians better counsel patients about cardiovascular risk. CCTS-supported early career faculty and pilot awardees have completed 18 patent filings and disclosed more than 25 inventions.
Be the first to know about exciting breakthroughs at
SUBSCRIBE TO EMAIL UPDATES
The Ohio State University College of Medicine.
EXPLORE MORE STORIES
About Dr. Jackson
Rebecca Jackson, MD, is a nationally recognized translational clinician-scientist who studies women's health with a focus on defining clinical factors, biomarkers and genetic associations for diseases that disproportionately or uniquely affect women, including osteoporotic fractures, cardiovascular disease, cancer and osteoarthritis.
Together with her collaborators in the Women's Health Initiative, she elucidated the risks and benefits of hormone therapy and calcium plus vitamin D therapy to reduce risk for osteoporotic fracture. Her laboratory has received continuous funding for the last 30 years from the National Heart, Lung, and Blood Institute; the National Institute on Aging; and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Jackson has authored or co-authored more than 250 peer-reviewed manuscripts.